JP2011511804A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011511804A5 JP2011511804A5 JP2010546054A JP2010546054A JP2011511804A5 JP 2011511804 A5 JP2011511804 A5 JP 2011511804A5 JP 2010546054 A JP2010546054 A JP 2010546054A JP 2010546054 A JP2010546054 A JP 2010546054A JP 2011511804 A5 JP2011511804 A5 JP 2011511804A5
- Authority
- JP
- Japan
- Prior art keywords
- ifnα
- inducible
- expression profile
- marker expression
- therapeutic agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000014509 gene expression Effects 0.000 claims 17
- 239000003550 marker Substances 0.000 claims 13
- 239000003814 drug Substances 0.000 claims 7
- 230000000694 effects Effects 0.000 claims 6
- 102100002849 IFI44L Human genes 0.000 claims 4
- 101710007500 IFI44L Proteins 0.000 claims 4
- 108060006892 RSAD2 Proteins 0.000 claims 4
- 102100002500 RSAD2 Human genes 0.000 claims 4
- 102100018943 IFI27 Human genes 0.000 claims 3
- 101700058576 IFI27 Proteins 0.000 claims 3
- 102100018942 IFI44 Human genes 0.000 claims 3
- 108060003862 IFI44 Proteins 0.000 claims 3
- 102000004965 antibodies Human genes 0.000 claims 3
- 108090001123 antibodies Proteins 0.000 claims 3
- 239000003124 biologic agent Substances 0.000 claims 3
- YMZPQKXPKZZSFV-CPWYAANMSA-N 2-[3-[(1R)-1-[(2S)-1-[(2S)-2-[(1R)-cyclohex-2-en-1-yl]-2-(3,4,5-trimethoxyphenyl)acetyl]piperidine-2-carbonyl]oxy-3-(3,4-dimethoxyphenyl)propyl]phenoxy]acetic acid Chemical compound C1=C(OC)C(OC)=CC=C1CC[C@H](C=1C=C(OCC(O)=O)C=CC=1)OC(=O)[C@H]1N(C(=O)[C@@H]([C@H]2C=CCCC2)C=2C=C(OC)C(OC)=C(OC)C=2)CCCC1 YMZPQKXPKZZSFV-CPWYAANMSA-N 0.000 claims 2
- GTVAUHXUMYENSK-RWSKJCERSA-N 2-[3-[(1R)-3-(3,4-dimethoxyphenyl)-1-[(2S)-1-[(2S)-2-(3,4,5-trimethoxyphenyl)pent-4-enoyl]piperidine-2-carbonyl]oxypropyl]phenoxy]acetic acid Chemical compound C1=C(OC)C(OC)=CC=C1CC[C@H](C=1C=C(OCC(O)=O)C=CC=1)OC(=O)[C@H]1N(C(=O)[C@@H](CC=C)C=2C=C(OC)C(OC)=C(OC)C=2)CCCC1 GTVAUHXUMYENSK-RWSKJCERSA-N 0.000 claims 2
- 101700027702 CYSD1 Proteins 0.000 claims 2
- 102100020192 EPSTI1 Human genes 0.000 claims 2
- 101710030058 EPSTI1 Proteins 0.000 claims 2
- 102100003091 HERC5 Human genes 0.000 claims 2
- 101700005474 HERC5 Proteins 0.000 claims 2
- 102100018941 IFI6 Human genes 0.000 claims 2
- 101700059813 IFI6 Proteins 0.000 claims 2
- 101700084153 IFIT1 Proteins 0.000 claims 2
- 102100018939 IFIT1 Human genes 0.000 claims 2
- 102100010000 IFIT3 Human genes 0.000 claims 2
- 101700040892 IFIT3 Proteins 0.000 claims 2
- 102100002949 ISG15 Human genes 0.000 claims 2
- 101700043176 ISG15 Proteins 0.000 claims 2
- 102000006992 Interferon-alpha Human genes 0.000 claims 2
- 108010047761 Interferon-alpha Proteins 0.000 claims 2
- 102100010057 MX1 Human genes 0.000 claims 2
- 101700058845 MX1 Proteins 0.000 claims 2
- 101700016688 OAS1 Proteins 0.000 claims 2
- 102100010861 OAS1 Human genes 0.000 claims 2
- 101700062170 OAS3 Proteins 0.000 claims 2
- 102100010863 OAS3 Human genes 0.000 claims 2
- 101710041676 cysl-1 Proteins 0.000 claims 2
- 230000001105 regulatory Effects 0.000 claims 2
- 210000004369 Blood Anatomy 0.000 claims 1
- 102100005968 LAMP3 Human genes 0.000 claims 1
- 101700017305 LAMP3 Proteins 0.000 claims 1
- 102100011000 LY6E Human genes 0.000 claims 1
- 101700048317 LY6E Proteins 0.000 claims 1
- 210000003205 Muscles Anatomy 0.000 claims 1
- 101700086999 OAS2 Proteins 0.000 claims 1
- 102100010862 OAS2 Human genes 0.000 claims 1
- 102100019176 RTP4 Human genes 0.000 claims 1
- 101700018972 RTP4 Proteins 0.000 claims 1
- 102100018868 SIGLEC1 Human genes 0.000 claims 1
- 101710017790 SIGLEC1 Proteins 0.000 claims 1
- 210000002966 Serum Anatomy 0.000 claims 1
- 101710009614 USP18 Proteins 0.000 claims 1
- 102100005067 USP18 Human genes 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 230000004547 gene signature Effects 0.000 claims 1
- 230000000051 modifying Effects 0.000 claims 1
- 201000002481 myositis Diseases 0.000 claims 1
- 230000002018 overexpression Effects 0.000 claims 1
- 150000003384 small molecules Chemical group 0.000 claims 1
Claims (15)
- 治療薬を用いた処置を受けている患者の、筋炎疾患の進行を監視する方法であって、
前記患者からの第１の試料の第１のＩＦＮα誘発性ＰＤマーカー発現プロファイルを得るステップと、
治療薬の投与後の前記患者からの第２の試料の第２のＩＦＮα誘発性ＰＤマーカー発現プロファイルを得るステップと、
前記第１のＩＦＮα誘発性ＰＤマーカー発現プロファイルを、前記第２のＩＦＮα誘発性ＰＤマーカー発現プロファイルと比較するステップと、
を含み、前記第１のＩＦＮα誘発性ＰＤマーカー発現プロファイル及び前記第２のＩＦＮα誘発性ＰＤマーカー発現プロファイルにおける変動は、前記治療薬の有効性のレベルを示す、前記方法。 - 前記第１のＩＦＮα誘発性ＰＤマーカー発現プロファイルが、遺伝子ＥＰＳＴＩ１、ＨＥＲＣ５、ＩＦＩ２７、ＩＦＩ４４、ＩＦＩ４４Ｌ、ＩＦＩ６、ＩＦＩＴ１、ＩＦＩＴ３、ＩＳＧ１５、ＬＡＭＰ３、ＬＹ６Ｅ、ＭＸ１、ＯＡＳ１、ＯＡＳ２、ＯＡＳ３、ＲＳＡＤ２、ＲＴＰ４、ＳＩＧＬＥＣ１及びＵＳＰ１８の過剰発現又は活性を含む遺伝子プロファイルの上方制御された発現又は活性を含む、請求項１に記載の方法。
- 前記治療薬が小分子又は生物学的薬剤である、請求項１に記載の方法。
- 前記治療薬がＩＦＮαに結合し、その活性を調節する生物学的薬剤である、請求項１に記載の方法。
- 前記生物学的薬剤が抗体である、請求項４に記載の方法。
- 前記抗体がＭＥＤＩ−５４５である、請求項５に記載の方法。
- 前記抗体が少なくとも１つのＩＦＮαサブタイプに結合するが、ＭＥＤＩ−５４５ではない、請求項５に記載の方法。
- 前記第１のＩＦＮα誘発性ＰＤマーカー発現プロファイルが、前記治療薬の投与の前に得られる、請求項１に記載の方法。
- 前記第１のＩＦＮα誘発性ＰＤマーカー発現プロファイルが、前記治療薬の投与の時点で得られる、請求項１に記載の方法。
- 前記第１の試料及び前記第２の試料が全血、筋肉又は血清である、請求項１に記載の方法。
- 前記第１のＩＦＮα誘発性ＰＤマーカー発現プロファイルが、遺伝子ＩＦＩ２７、ＲＳＡＤ２、ＩＦＩ４４Ｌ、ＩＦＩ４４、ＯＡＳ１、ＩＦＩＴ１、ＩＳＧ１５、ＯＡＳ３、ＨＥＲＣ５、ＭＸ１、ＥＰＳＴＩ１、ＩＦＩＴ３及びＩＦＩ６の上方制御された発現又は活性を含む、請求項１に記載の方法。
- 前記第１のＩＦＮα誘発性ＰＤマーカー発現プロファイルが、遺伝子ＩＦＩ４４Ｌ、ＲＳＡＤ２、ＩＦＩ２７及びＩＦＩ４４の上方制御された発現又は活性を含む、請求項１に記載の方法。
- 前記第１のＩＦＮα誘発性ＰＤマーカー発現プロファイルが、遺伝子ＩＦＩ４４Ｌ及びＲＳＡＤ２の上方制御された発現又は活性を含む、請求項１に記載の方法。
- 前記第１のＩＦＮα誘発性ＰＤマーカー発現プロファイルが、中程度のＩ型ＩＦＮ又はＩＦＮα誘発性遺伝子サインスコアを含む、請求項１に記載の方法。
- 前記中程度のスコアが、４以上であるが、１０未満のスコアである、請求項１４に記載の方法。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US696308P | 2008-02-08 | 2008-02-08 | |
| PCT/US2009/033407 WO2009100342A2 (en) | 2008-02-08 | 2009-02-06 | Disease markers and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011511804A JP2011511804A (ja) | 2011-04-14 |
| JP2011511804A5 true JP2011511804A5 (ja) | 2012-03-15 |
Family
ID=40952717
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010546054A Pending JP2011511804A (ja) | 2008-02-08 | 2009-02-06 | 疾患マーカーおよびその使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20110262928A1 (ja) |
| EP (2) | EP2848702A1 (ja) |
| JP (1) | JP2011511804A (ja) |
| KR (1) | KR20110005783A (ja) |
| CN (1) | CN101999001B (ja) |
| AU (1) | AU2009212216B2 (ja) |
| BR (1) | BRPI0908065A2 (ja) |
| CA (1) | CA2714410A1 (ja) |
| ES (1) | ES2529593T3 (ja) |
| HK (1) | HK1150063A1 (ja) |
| MX (1) | MX2010008698A (ja) |
| SG (1) | SG188147A1 (ja) |
| WO (1) | WO2009100342A2 (ja) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100190659A1 (en) * | 2007-07-12 | 2010-07-29 | The Brigham And Women's Hospital, Inc. | Compositions and Methods for Diagnosing and Assessing Inflammatory Myopathies |
| KR20220008944A (ko) | 2008-01-18 | 2022-01-21 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 체액 내에서 질병 또는 병태의 시그너쳐의 검출 방법 |
| US8785414B2 (en) * | 2009-03-31 | 2014-07-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Differentially expressed microRNAs as biomarkers for the diagnosis and treatment of Sjögren's syndrome |
| WO2011028933A1 (en) * | 2009-09-03 | 2011-03-10 | Medimmune, Llc | Type 1 interferon diagnostic |
| WO2011126105A1 (ja) * | 2010-04-08 | 2011-10-13 | 三菱化学メディエンス株式会社 | 免疫系の異常疾患または関節系の異常疾患への罹患またはこれらの病勢を判定するための検査方法 |
| WO2012012725A2 (en) | 2010-07-23 | 2012-01-26 | President And Fellows Of Harvard College | Methods of detecting diseases or conditions using phagocytic cells |
| CA2806304A1 (en) | 2010-07-23 | 2012-01-26 | President And Fellows Of Harvard College | Methods of detecting prenatal or pregnancy-related diseases or conditions |
| US20130184178A1 (en) | 2010-07-23 | 2013-07-18 | President And Fellows Of Harvard College | Methods of Detecting Autoimmune or Immune-Related Diseases or Conditions |
| JP2013538565A (ja) | 2010-07-23 | 2013-10-17 | プレジデント アンド フェロウズ オブ ハーバード カレッジ | 体液中の疾患または症状のシグネチャを検出する方法 |
| EP2742148B1 (en) * | 2011-08-11 | 2017-06-28 | Hummingbird Diagnostics GmbH | Complex sets of mirnas as non-invasive biomarkers for psoriasis |
| ITRM20110685A1 (it) | 2011-12-23 | 2013-06-24 | Internat Ct For Genetic En Gineering And | Microrna per la rigenerazione cardiaca attraverso l induzione della proliferazione dei miociti cardiaci |
| EP2653554A1 (en) * | 2012-04-17 | 2013-10-23 | Istituto Nazionale Di Genetica Molecolare-INGM | Immune response biomarkers |
| EP2965077B1 (en) | 2013-03-09 | 2022-07-13 | Harry Stylli | Methods of detecting cancer |
| EP2965086A4 (en) | 2013-03-09 | 2017-02-08 | Harry Stylli | Methods of detecting prostate cancer |
| WO2014209238A1 (en) * | 2013-06-28 | 2014-12-31 | Acumen Research Laboratories Pte. Ltd. | Sepsis biomarkers and uses thereof |
| EP3191846A4 (en) | 2014-09-11 | 2018-06-13 | Harry Stylli | Methods of detecting prostate cancer |
| JP6531306B2 (ja) * | 2015-02-20 | 2019-06-19 | 一三 西野 | 炎症性筋疾患鑑別マーカー及びそれを用いた炎症性筋疾患と非炎症性筋疾患の鑑別方法 |
| CN108379584B (zh) * | 2018-04-12 | 2020-08-11 | 上海交复生物医药科技有限公司 | RSAD2通过wnt通路影响肿瘤细胞替莫唑胺耐药性 |
| EP3784270A1 (en) * | 2018-04-27 | 2021-03-03 | Stemline Therapeutics Inc. | Methods of treating an autoimmune disease with a human interleukin-3 (il-3)-diphtheria toxin conjugate (dt-il3) |
| CN110085282A (zh) * | 2019-04-23 | 2019-08-02 | 华中师范大学 | 核酸结构中核苷酸与核苷酸相互作用预测的方法 |
| CN110108880A (zh) * | 2019-05-30 | 2019-08-09 | 四川大学华西医院 | Fez1自身抗体检测试剂在制备肺癌筛查试剂盒中的用途 |
| CN110161235B (zh) * | 2019-06-26 | 2022-04-12 | 江苏省中医院 | 三种血清蛋白联合用于强直性脊柱炎诊断的用途 |
| CA3152279A1 (en) * | 2019-10-04 | 2021-04-08 | The Regents Of The University Of Michigan | Methods for determining responsiveness to anti-tumor necrosis factor therapy in the treatment of psoriasis |
| CN111378742A (zh) * | 2020-04-16 | 2020-07-07 | 嘉兴程瑞医药科技有限公司 | microRNA生物标志物及其在制备自身免疫疾病检测试剂盒中的应用 |
| CN113388677A (zh) * | 2021-06-17 | 2021-09-14 | 河北医科大学第二医院 | 包括ifi44的干燥症诊断标志物组合 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8303165D0 (en) | 1983-02-04 | 1983-03-09 | Secher D S | Monoclonal antibody |
| JPS60500864A (ja) | 1983-02-04 | 1985-06-06 | ワドリ、テクナラジズ、インコーパレイティド | 近縁関係にあるが別個のタンパク質間に存在する共通決定基に対して特異的なハイブリド−マ抗体の製造および特性づけ |
| DE3306060A1 (de) | 1983-02-22 | 1984-08-23 | Boehringer Ingelheim International GmbH, 6507 Ingelheim | Neue immunglobulin-produzierende hybridzellinien, deren verwendung und verfahren zu deren herstellung |
| EP0205404B1 (en) | 1985-06-11 | 1992-07-15 | Ciba-Geigy Ag | Hybrid interferons |
| US7087726B2 (en) | 2001-02-22 | 2006-08-08 | Genentech, Inc. | Anti-interferon-α antibodies |
| US20070166281A1 (en) * | 2004-08-21 | 2007-07-19 | Kosak Kenneth M | Chloroquine coupled antibodies and other proteins with methods for their synthesis |
| US7833795B2 (en) * | 2004-08-24 | 2010-11-16 | The Trustees Of The University Of Pennsylvania | Assessment of cardiovascular risk using isoprostane biomarkers and COX-2 selective inhibitors |
| US20070065844A1 (en) * | 2005-06-08 | 2007-03-22 | Massachusetts Institute Of Technology | Solution-based methods for RNA expression profiling |
| SI2327792T1 (sl) * | 2005-08-05 | 2013-12-31 | Genentech, Inc. | Postopki in sestavki za detektiranje avtoimunskih motenj |
| US20100143373A1 (en) * | 2006-12-06 | 2010-06-10 | Medimmune, Llc | Methods of treating systemic lupus erythematosus |
-
2009
- 2009-02-06 KR KR1020107019933A patent/KR20110005783A/ko not_active Application Discontinuation
- 2009-02-06 EP EP14191479.6A patent/EP2848702A1/en not_active Withdrawn
- 2009-02-06 CN CN2009801123932A patent/CN101999001B/zh active Active
- 2009-02-06 JP JP2010546054A patent/JP2011511804A/ja active Pending
- 2009-02-06 BR BRPI0908065-1A patent/BRPI0908065A2/pt not_active IP Right Cessation
- 2009-02-06 ES ES09709316.5T patent/ES2529593T3/es active Active
- 2009-02-06 WO PCT/US2009/033407 patent/WO2009100342A2/en active Application Filing
- 2009-02-06 MX MX2010008698A patent/MX2010008698A/es active IP Right Grant
- 2009-02-06 AU AU2009212216A patent/AU2009212216B2/en active Active
- 2009-02-06 SG SG2013010608A patent/SG188147A1/en unknown
- 2009-02-06 US US12/866,586 patent/US20110262928A1/en not_active Abandoned
- 2009-02-06 CA CA2714410A patent/CA2714410A1/en not_active Abandoned
- 2009-02-06 EP EP09709316.5A patent/EP2252703B1/en active Active
-
2011
- 2011-04-18 HK HK11103859.1A patent/HK1150063A1/xx unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011511804A5 (ja) | ||
| JP2014519487A5 (ja) | ||
| JP2010526107A5 (ja) | ||
| Ursin et al. | Sex differences in respiratory viral pathogenesis and treatments | |
| Xiao et al. | High‐throughput RNA sequencing of a formalin‐fixed, paraffin‐embedded autopsy lung tissue sample from the 1918 influenza pandemic | |
| Taubenberger et al. | Reconstruction of the 1918 influenza virus: unexpected rewards from the past | |
| JP2013503642A5 (ja) | ||
| Fang et al. | Molecular characterization of in vivo adjuvant activity in ferrets vaccinated against influenza virus | |
| RU2012112802A (ru) | Диагностика интерферона типа 1 | |
| JP2011509071A5 (ja) | ||
| RU2014127178A (ru) | Фармакодинамические маркеры, индуцированные интерфероном альфа2009125616 06.12.2006 | |
| JP2008546390A5 (ja) | ||
| Menicucci et al. | Antiviral innate responses induced by VSV-EBOV vaccination contribute to rapid protection | |
| JP2019528081A5 (ja) | ||
| JP2010512315A5 (ja) | ||
| JP2005511076A5 (ja) | ||
| WO2017156015A3 (en) | Micrornas and methods of their use | |
| JP2014520529A5 (ja) | ||
| JP2009535036A5 (ja) | ||
| JP2010535786A5 (ja) | ||
| RU2010146701A (ru) | Противовирусная терапия | |
| JP2014530819A5 (ja) | ||
| Younossi et al. | Early gene expression profiles of patients with chronic hepatitis C treated with pegylated interferon‐alfa and ribavirin | |
| Gergely Jr et al. | Detection of TT virus in patients with idiopathic inflammatory myopathies | |
| JP2013505008A5 (ja) |